These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 22545496)

  • 1. [Injectable soft tissue fillers: are they medical devices or drugs? Implications for HIV lipodystrophy].
    Nikolic DS; Balagué N; Campanelli A; Elias B; Calmy A; Toutous-Trellu L
    Rev Med Suisse; 2012 Apr; 8(335):747-53. PubMed ID: 22545496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison between lipofilling and a nonabsorbable filler for facial wasting rehabilitation in HIV-positive patients.
    Rauso R; Curinga G; Santillo V; Corvo G; Tartaro G
    J Craniofac Surg; 2011 Sep; 22(5):1684-8. PubMed ID: 21959413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of facial lipoatrophy via autologous fat transfer.
    Cohen G; Treherne A
    J Drugs Dermatol; 2009 May; 8(5):486-9. PubMed ID: 19537373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case of HIV-associated facial lipoatrophy treated with 1000-cs liquid injectable silicone.
    Orentreich D; Leone AS
    Dermatol Surg; 2004 Apr; 30(4 Pt 1):548-51. PubMed ID: 15056149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Polylactic acid injections: usefullness for the treatment of facial lipoatrophy in HIV+ patients under tritherapy].
    Piquet M; Brignol L; Chatelain B; Rey D; Ricbourg B; Meyer C
    Rev Stomatol Chir Maxillofac; 2007 Dec; 108(6):496-504. PubMed ID: 17675198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Poly-L-lactic-acid filling of facial lipoatrophy in HIV+ patients under tritherapy].
    Thiéry G; Coulet O; Adam S; Guyot L
    Rev Stomatol Chir Maxillofac; 2008 Apr; 109(2):103-5. PubMed ID: 18374957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review of permanent and semipermanent dermal fillers for HIV-associated facial lipoatrophy.
    Sturm LP; Cooter RD; Mutimer KL; Graham JC; Maddern GJ
    AIDS Patient Care STDS; 2009 Sep; 23(9):699-714. PubMed ID: 19673594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective, open-label, 18-month trial of calcium hydroxylapatite (Radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: one-year durability.
    Silvers SL; Eviatar JA; Echavez MI; Pappas AL
    Plast Reconstr Surg; 2006 Sep; 118(3 Suppl):34S-45S. PubMed ID: 16936543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient satisfaction following Bio-Alcamid injection for facial contour defects.
    George DA; Erel E; Waters R
    J Plast Reconstr Aesthet Surg; 2012 Dec; 65(12):1622-6. PubMed ID: 22749703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost consequences of HIV-associated lipoatrophy.
    Hornberger J; Rajagopalan R; Shewade A; Loutfy MR
    AIDS Care; 2009 May; 21(5):664-71. PubMed ID: 19444676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of lipoatrophy and aging: volume deficits in the face.
    Coleman S; Saboeiro A; Sengelmann R
    Aesthetic Plast Surg; 2009 Jan; 33(1):14-21. PubMed ID: 18987910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effect of polyalkylimide gel injections on severity of facial lipoatrophy and quality of life of HIV-positive patients.
    Karim RB; de Lint CA; van Galen SR; van Rozelaar L; Nieuwkerk PT; Askarizadeh E; Hage JJ
    Aesthetic Plast Surg; 2008 Nov; 32(6):873-8. PubMed ID: 18551339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV facial lipoatrophy: causes and treatment options.
    Jones D
    Dermatol Surg; 2005 Nov; 31(11 Pt 2):1519-29; discussion 1529. PubMed ID: 16416634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Porcine filler for facial lipoatrophy associated with human immunodeficiency virus treatment.
    Reytan N; Rzany B
    J Drugs Dermatol; 2008 Sep; 7(9):884-6. PubMed ID: 19112805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A ribose-crosslinked collagen filler treatment for facial lipoatrophy associated with the treatment of human immunodeficiency virus.
    Reytan N; Rzany B
    J Drugs Dermatol; 2008 Dec; 7(12):1169-71. PubMed ID: 19137772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of Sculptra: a review of clinical trial data.
    Engelhard P; Humble G; Mest D
    J Cosmet Laser Ther; 2005 Dec; 7(3-4):201-5. PubMed ID: 16414909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of facial lipoatrophy by lipofilling in HIV infected patients: retrospective study on 317 patients on 9 years].
    Uzzan C; Boccara D; Lacheré A; Mimoun M; Chaouat M
    Ann Chir Plast Esthet; 2012 Jun; 57(3):210-6. PubMed ID: 22218365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dermal fillers for facial soft tissue augmentation.
    Dastoor SF; Misch CE; Wang HL
    J Oral Implantol; 2007; 33(4):191-204. PubMed ID: 17912960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of facial lipoatrophy in HIV-infected patients.
    Prescrire Int; 2008 Aug; 17(96):170. PubMed ID: 19492497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complications after treatment with polyalkylimide.
    Schelke L
    Dermatol Surg; 2011 Jan; 37(1):125. PubMed ID: 21070467
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.